02/14/19
Ironwood Pharmaceuticals Inc IRWD incurred fourth quarter 2018 adjusted loss of 2 cents per share narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the loss of 14 cents in the year ago period Total revenues in the fourth quarter were 130 7 million reflecting
02/13/19
What happened After reporting fourth quarter financial results that were better than expected on both the top and bottom line and updating investors on its plans to split into two companies Ironwood Pharmaceuticals NASDAQ IRWD surged 11 7 higher today So
02/13/19
Image source The Motley Fool Ironwood Pharmaceuticals Inc NASDAQ IRWD Q4 160 2018 Earnings Conference Call Feb 13 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared
02/13/19
Ironwood Pharmaceuticals IRWD came out with a quarterly loss of 0 02 per share versus the Zacks Consensus Estimate of a loss of 0 17 This compares to loss of 0 14 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings
02/06/19
Wall Street expects a year over year decline in earnings on lower revenues when Ironwood Pharmaceuticals IRWD reports results for the quarter ended December 2018 While this widely known consensus outlook is important in gauging the company s earnings picture a powerful factor that could
01/29/19
Allergan plc s AGN fourth quarter 2018 earnings came in at 4 29 per share which beat the Zacks Consensus Estimate of 4 15 However earnings fell 11 7 year over year mainly due to lower revenues Revenues came in at 4 08 billion which exceeded the Zacks Consensus Estimate of 3
01/24/19
Ironwood Pharmaceuticals Inc IRWD announced that it has initiated a phase I study on its orally administered central nervous system CNS penetrant soluble guanylate cyclase sGC stimulator IW 6463 The candidate is currently being evaluated for the treatment of serious and orphan
IRWD - Ironwood Pharmaceuticals